Johanne I Weberpals

Summary

Affiliation: University of Ottawa
Country: Canada

Publications

  1. doi request reprint A rare case of ectopic adrenocorticotropic hormone syndrome in small cell carcinoma of the vagina: a case report
    Johanne Weberpals
    Division of Gynaecologic Oncology, The Ottawa Hospital, Canada
    J Low Genit Tract Dis 12:140-5. 2008
  2. pmc The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells
    Johanne I Weberpals
    Division of Gynaecologic Oncology, The Ottawa Hospital, 501 Smyth Road, Ottawa, K1H 8L6, Canada
    Cancer Cell Int 11:29. 2011
  3. pmc Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review
    O Bougie
    The Department of Obstetrics, Gynaecology, and Newborn Care, The Ottawa Hospital, Ottawa, ON, Canada K1H 8L6
    Int J Surg Oncol 2011:374012. 2011
  4. pmc BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer
    Katherine V Clark-Knowles
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON, Canada K1H 8L6
    J Oncol 2010:891059. 2010
  5. pmc EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer
    Alexandria M Haslehurst
    Department of Pathology and Molecular Medicine, Queen s University, Kingston, ON, Canada
    BMC Cancer 12:91. 2012
  6. doi request reprint Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study
    J I Weberpals
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, Ontario, Canada
    Ann Oncol 22:2403-10. 2011
  7. doi request reprint The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer
    Johanne Weberpals
    Division of Gynaecologic Oncology, The Ottawa Hospital, Ottawa, Ontario, Canada
    Int J Cancer 124:806-15. 2009
  8. doi request reprint Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway
    Johanne I Weberpals
    Ottawa Hospital, Division of Gynaecologic Oncology, Centre for Cancer Therapeutics, Ottawa Health Research Institute, Ottawa, Ontario, Canada
    J Clin Oncol 26:3259-67. 2008
  9. ncbi request reprint Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia
    Tien Le
    Division of Gynecologic Oncology, Ottawa General Hospital, 501 Smyth Road Room 8130, Ottawa, Ontario, Canada K1H 8L6
    Gynecol Oncol 106:579-84. 2007
  10. doi request reprint Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer
    Johanne I Weberpals
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
    Cancer Genet 204:525-35. 2011

Collaborators

Detail Information

Publications11

  1. doi request reprint A rare case of ectopic adrenocorticotropic hormone syndrome in small cell carcinoma of the vagina: a case report
    Johanne Weberpals
    Division of Gynaecologic Oncology, The Ottawa Hospital, Canada
    J Low Genit Tract Dis 12:140-5. 2008
    ..To describe ectopic adrenocorticotropic hormone (ACTH) syndrome (EAS) to increase awareness of this condition when treating patients with gynecological small cell carcinoma (SmCC)...
  2. pmc The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells
    Johanne I Weberpals
    Division of Gynaecologic Oncology, The Ottawa Hospital, 501 Smyth Road, Ottawa, K1H 8L6, Canada
    Cancer Cell Int 11:29. 2011
    ..abstract:..
  3. pmc Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review
    O Bougie
    The Department of Obstetrics, Gynaecology, and Newborn Care, The Ottawa Hospital, Ottawa, ON, Canada K1H 8L6
    Int J Surg Oncol 2011:374012. 2011
    ..This review outlines salient aspects in the approach to patients at high risk of developing breast and ovarian cancer, including criteria for genetic testing, screening guidelines, surgical prophylaxis, and chemoprevention...
  4. pmc BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer
    Katherine V Clark-Knowles
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON, Canada K1H 8L6
    J Oncol 2010:891059. 2010
    ..The aim of this paper is to provide an understanding of how BRCA1 has evolved into a promising target for the treatment of sporadic disease and to outline the main potential small molecule inhibitors of BRCA1 in EOC...
  5. pmc EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer
    Alexandria M Haslehurst
    Department of Pathology and Molecular Medicine, Queen s University, Kingston, ON, Canada
    BMC Cancer 12:91. 2012
    ..The role of EMT in embryogenesis is well-characterized and increasing evidence suggests that elements of the transition may be important in other processes, including metastasis and drug resistance in various different cancers...
  6. doi request reprint Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study
    J I Weberpals
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, Ontario, Canada
    Ann Oncol 22:2403-10. 2011
    ..Breast cancer 1 (BRCA1) protein inactivation in sporadic ovarian carcinoma (OC) is common and low BRCA1 expression is linked with platinum sensitivity. The clinical validation of BRCA1 as a prognostic marker in OC remains unresolved...
  7. doi request reprint The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer
    Johanne Weberpals
    Division of Gynaecologic Oncology, The Ottawa Hospital, Ottawa, Ontario, Canada
    Int J Cancer 124:806-15. 2009
    ..In summary, this study shows that low BRCA1 and ERCC1 expression correlate with improved survival in advanced OC and HDAC inhibition induces synergistic cytotoxicity with platinum in vitro...
  8. doi request reprint Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway
    Johanne I Weberpals
    Ottawa Hospital, Division of Gynaecologic Oncology, Centre for Cancer Therapeutics, Ottawa Health Research Institute, Ottawa, Ontario, Canada
    J Clin Oncol 26:3259-67. 2008
    ..This will determine whether BRCA1 has relevance as a predictive and prognostic marker in SEOC and whether aberrations in the BRCA1 pathway warrant further study as potential therapeutic targets...
  9. ncbi request reprint Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia
    Tien Le
    Division of Gynecologic Oncology, Ottawa General Hospital, 501 Smyth Road Room 8130, Ottawa, Ontario, Canada K1H 8L6
    Gynecol Oncol 106:579-84. 2007
    ..To investigate the activity of 5% Imiquimod cream in the primary treatment of vulva intraepithelial neoplasia (VIN) grade 2/3...
  10. doi request reprint Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer
    Johanne I Weberpals
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
    Cancer Genet 204:525-35. 2011
    ....
  11. doi request reprint Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection
    Fabrice Le Boeuf
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
    Int J Cancer 131:E204-15. 2012
    ..Taken together, these results demonstrate that HPV-infected cells are susceptible to oncolytic virus therapy and that this approach may represent a novel therapeutic approach in HPV positive CC and HNSCC patients...